supplementary material

[키워드] adjuvant Administered Adverse age alanine aminotransferase All study participant allergy approved ARDS Aspartate transaminase Aspirin atorvastatin benefit bleeding block randomization Breastfeeding C-reactive protein characterized clinical Clinical deterioration Clinical improvement Clinical outcome Coagulopathy collected data computer-generated conducted confirmed case control group COVID-19 COVID-19 patient COVID-19 patients CPK creatine phosphokinase Critical derivative discharge dissemination dose drug drug interaction ECMO Effect element Endotracheal intubation enrolment ethical committee evaluated examined excluded exclusion criteria Final Hepatitis HIV Hospital admission hospital discharge hospitalisation ICMR ICU admission in-hospital mortality include Inclusion India infected with SARS-CoV-2 Inflammatory marker interim analysis liver management mechanical ventilation Medical Science medication Mortality myalgia National Cancer Institute New Non-invasive number objective Open-label Other outbreak outcome outcomes pandemic parallel-group participant Patient patients Platelet Pregnancy Primary outcome progression Protease inhibitor protease inhibitors protocol randomised Randomised control trial randomised controlled trial randomize Randomized receiving recruited recruitment reference Registered registry renal replacement therapy respiratory RT-PCR Sample size SARS-CoV-2 SARS-COV-2 infection secondary outcome serum Shock statin status study period Study protocol supplementary material symptom onset Tablet therapy Treatment protocol Trial troponin usual care website WHO written consent written Informed Consent
[DOI] 10.1186/s13063-020-04840-y PMC 바로가기 [Article Type] Letter